Thursday, April 01, 2021 12:59:37 AM
Grip,
That's a lengthy list and indeed depressing information.
If that's the lense your viewing things through then I hope you didn't have your shares in a Roth (can't really take the losses - a downside). And you either are still holding or just expressing your dismay in a crowded room. I'm down significantly as well, but that's why I limit the speculative portion of my portfolio.
"Mama said there'd be days like this, Mama said..."
I don't share your pessimism. If anything, I really feel we're in the midst of an almost "perfect storm." It's not a Happy Storm, because it's built upon a mountain of dead fellow citizens, but we hold an answer, in fact a significant number of answers. The resistance of Big Pharma and its long tentacles have a quandary. They can't immediately come up with a match for leronlimab, yet the bodies continue to mount daily. Their minions are trying to dodge spotlights as people on this board and elsewhere, educate others, apply pressure, and pull back the curtain. Can BP and its heartles minions continue to hold back leronlimab from the dying? For how long? At what cost? How many mountains of needless dead are tolerable?
...And those holding leronlimab back are also potential fodder for the reaper. The vaccines are an increasingly feeble wall as ignorance enables, in fact assists the virus to enhance its bag of tricks. The complicit will view leronlimab with different eyes, when it affects them and those they love.
Meanwhile, Nader, Kelly and crew struggle on. ...there is light at the end of he tunnel and I don't think it's the train.
If this investment is too painful, then walking away will eventually bring some needed relief. It's up to you.
That's a lengthy list and indeed depressing information.
If that's the lense your viewing things through then I hope you didn't have your shares in a Roth (can't really take the losses - a downside). And you either are still holding or just expressing your dismay in a crowded room. I'm down significantly as well, but that's why I limit the speculative portion of my portfolio.
"Mama said there'd be days like this, Mama said..."
I don't share your pessimism. If anything, I really feel we're in the midst of an almost "perfect storm." It's not a Happy Storm, because it's built upon a mountain of dead fellow citizens, but we hold an answer, in fact a significant number of answers. The resistance of Big Pharma and its long tentacles have a quandary. They can't immediately come up with a match for leronlimab, yet the bodies continue to mount daily. Their minions are trying to dodge spotlights as people on this board and elsewhere, educate others, apply pressure, and pull back the curtain. Can BP and its heartles minions continue to hold back leronlimab from the dying? For how long? At what cost? How many mountains of needless dead are tolerable?
...And those holding leronlimab back are also potential fodder for the reaper. The vaccines are an increasingly feeble wall as ignorance enables, in fact assists the virus to enhance its bag of tricks. The complicit will view leronlimab with different eyes, when it affects them and those they love.
Meanwhile, Nader, Kelly and crew struggle on. ...there is light at the end of he tunnel and I don't think it's the train.
If this investment is too painful, then walking away will eventually bring some needed relief. It's up to you.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
